August appears to be month of bad news for clinical developments in non-small cell lung cancer (NSCLC). Following Bristol-Myers Squibb Co.'s shocking Phase III failure for Opdivo (nivolumab) in first-line NSCLC, Oncolytics Biotech Inc. has also reported disappointing data for its lung cancer drug Reolysin.
Oncolytics Biotech reported less than impressive Phase II NSCLC data for its cancer drug Reolysin (pelareorep) this week – and despite the company's best attempt to find statistical significant data in subgroup analyses, analysts are not convinced.
The Canadian firm reported on Aug. 10 data split by gender from the Phase II IND211 study, which enrolled patients...
The Belgian drugmaker is boosting its biologics capacity over the pond.
Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.
Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.
